MDT Cash & equivalents
Cash & equivalents at Medtronic fell to $1.9B in fiscal 2026, from $2.2B in 2025.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 1613103 · EDGAR ↗ · FY2022–FY2026 · ANNUAL
FY2026$1.9B
FY2025 $2.2B
HIGH$3.7B FY2022
LOW$1.3B FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2026 | $1.9B | $-269M |
| FY2025 | $2.2B | +$934M |
| FY2024 | $1.3B | $-259M |
| FY2023 | $1.5B | $-2.2B |
| FY2022 | $3.7B | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · MDT company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.